http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2012122106-A2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c5608d6ba8b72be5849e54388b98afb3 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b3127c0ebee3f865b211b019fac84286 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_9974e209620279719c6046a3476816bd |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57449 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5023 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-185 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-337 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-282 |
| filingDate | 2012-03-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c9258f8298828699717d5dbe0578fd6e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1d434059a0c148446f0f0cd5e9d7cd64 |
| publicationDate | 2012-09-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-2012122106-A2 |
| titleOfInvention | Compositions and methods apc, creb, and bad pathways to assess and affect cancer |
| abstract | Disclosed are compositions and methods for assessing the apoptosis and survival BAD phosphorylation pathway (BAD pathway); and/or (2) the cell cycle role of APC in cell cycle regulation pathway (APC pathway); and/or (3) the transcription CREB pathway (CREB pathway) and for using these pathways to assess, treat, monitor, prognose, diagnose, etc. subjects with cancer. Also disclosed are compositions and methods for identifying molecular pathways that are common to one or more chemotherapeutic agents for the treatment of an oncological disorder, for screening for compounds or agents that can be used to treat ovarian cancer, and for selecting for compounds or agents that can enhance the cytotoxic response of cisplatin, carboplatin, and/or paclitaxel against a cancer cell, such as an ovarian cancer cell or cell line. In some forms, the disclosed methods can comprise identifying compounds and/or agents that modulate the BAD pathway and/or the APC pathway; and/or the CREB pathway. In some forms, the disclosed methods can comprise method for treating cancer using compounds and/or agents that modulate the BAD pathway and/or the APC pathway; and/or the CREB pathway. Also disclosed are compositions, compounds, and agents identified using the disclosed methods. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-107220526-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-107220526-B http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-107203704-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-107203704-B |
| priorityDate | 2011-03-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 1072.